August 10, 2021 – Cardinal Health (Dublin, OH) announced it has formed partnerships with both Abbott and Quidel Corporation to commercialize and broaden access to over-the-counter rapid COVID-19 tests.
Cardinal Health will leverage its distribution network to support broad access to Quidel’s QuickVue At-Home OTC COVID-19 Test and Abbott’s BinaxNOW COVID-19 Antigen Self-Test, which allow consumers to easily perform tests for the virus without a prescription.
With the addition of rapid at-home tests, Cardinal Health says its laboratory products portfolio can now support customized testing and surveillance programs for workplaces, the travel and hospitality industry, and schools with comprehensive solutions that include at-home tests, rapid on-site testing, PCR (molecular testing) and on-site or at-home specimen collection.
Cardinal Health says that COVID-19 OTC rapid tests allow employers, schools and individuals to easily implement screening and surveillance testing programs to identify both symptomatic and asymptomatic infections. While the effort to vaccinate more Americans continues, these programs will also remain a vital piece in mitigating the spread of COVID-19 as new variants like Delta emerge and with the potential for the virus to reemerge seasonally.
In addition to providing COVID-19 OTC rapid tests, Cardinal Health Laboratory Products provides consumables, including swabs and viral transport media, as well as customizable specimen collection kits to support the testing needs of laboratories and decentralized testing sites.
It also provides a range of solutions for COVID-19 vaccine storage from the time it is manufactured until it’s administered.
Additionally, the company offers comprehensive testing solutions for respiratory viruses and other infectious diseases ranging from core lab molecular testing to rapid point-of-care platforms.